Brief: Invex Therapeutics Says Approval To Commence IIh Evolve Phase III Clinical Trial Received
19/03/2023 22:19
March 20 (Reuters) - Invex Therapeutics Ltd IXC.AX :
* APPROVAL TO COMMENCE IIH EVOLVE PHASE III CLINICAL TRIAL
RECEIVED FROM BUNDESINSTITUT FÜR ARZNEIMITTEL UND
MEDIZINPRODUKTE
Source text for Eikon: ID:nASX9r35QM
Further company coverage: IXC.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Invex Therapeutics
See all newsBrief: Invex Therapeutics Requests Trading Halt
Brief: Invex Therapeutics Says Narelle Warren Resigns As CFO
Brief: Invex Therapeutics' Negotiations Discontinued With Neurological Disease Therapeutics Development Co
Australia's Invex Therapeutics falls as agreement talks fade
Brief: Invex Therapeutics Seeks Trading Halt